Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs

被引：0
|
作者：
Ye, J. [1 ]
Liu, J. [1 ]
Yang, Y. [1 ]
Lv, W. [1 ]
Xu, W. [2 ]
Xia, P. [1 ]
Wang, L. [1 ]
Zhu, L. [1 ]
Hu, J. [1 ,3 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Peoples R China
[2] Sanmen Peoples Hosp, Taizhou, Peoples R China
[3] Key Lab Clin Evaluat Technol Med Device Zhejiang, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Anlotinib; NSCLC; EGFR-TKIs;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.04
引用
收藏
页码：S554 / S554
页数：1
相关论文
共 50 条
  • [41] Tamoxifen Might Enhance the Effect of EGFR-TKIs on EGFR-Mutant NSCLC Cells
    He, Y.
    Zhang, Q.
    Zheng, M.
    Chen, Z.
    Wei, X.
    Yang, X.
    Gao, X.
    Wu, Y.
    Liu, S.
    Zhou, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S242 - S242
  • [42] Chemotherapy plus EGFR-TKIs versus EGFR-TKIs Alone in Non-small Cell Lung Cancer with EGFR-Activating Mutations: A Meta-analysis
    Han, G.
    Peng, M.
    Weng, Y.
    Zou, J.
    Song, Q.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E458 - E458
  • [43] Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
    Wu, Xuan
    Liang, Wenhua
    Hou, Xue
    Lin, Zhong
    Zhao, Hongyun
    Huang, Yan
    Fang, Wenfeng
    Zhao, Yuanyuan
    Wu, Jingxun
    Yang, Yunpeng
    Xue, Chong
    Hu, Zhihuang
    Zhang, Jing
    Zhang, Jianwei
    Ma, Yuxiang
    Zhou, Ting
    Qin, Tao
    Zhang, Li
    ONCOTARGETS AND THERAPY, 2013, 6 : 1481 - 1491
  • [44] COMPARISON OF COST-EFFECTIVENESS BETWEEN EGFR-TKIS THERAPY AND CHEMOTHERAPY FOR ADVANCED NSCLC
    Zhang, T.
    Cai, S.
    Wu, C.
    Xu, J.
    Lin, T.
    Jiang, J.
    VALUE IN HEALTH, 2016, 19 (07) : A887 - A887
  • [45] Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
    Xu, Ziyi
    Teng, Fei
    Hao, Xuezhi
    Li, Junling
    Xing, Puyuan
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1891 - 1902
  • [46] Efficacy and Safety of Third-Generation EGFR-TKIs Combined with Radiotherapy for Advanced NSCLC with Typical EGFR Mutations: A Retrospective Study
    Zhang, Wen-xuan
    Xue, Hui-chan
    Zhao, Ye
    Xu, Shuang-bing
    CURRENT MEDICAL SCIENCE, 2025,
  • [47] THE PREFERABLE TIMING OF TREATMENT WITH EGFR-TKIS FOR NSCLCS WITH EGFR MUTATIONS
    Touge, Hirokazu
    Matsumoto, Shingo
    Sakamoto, Tomohiro
    Kinoshita, Naoki
    Matsunami, Keiji
    Kodani, Masahiro
    Nakamoto, Masaki
    Yamasaki, Akira
    Chikumi, Hiroki
    Kawasaki, Yuji
    Igishi, Tadashi
    Shimizu, Eiji
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1228 - S1228
  • [48] Efficacy of first-generation EGFR-TKIs on patients with NSCLC harboring EGFR uncommon mutations: a pooled analysis
    Zhang, Y.
    Tang, S.
    Zhang, J.
    He, Q.
    He, J.
    Liang, W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] THE CONCOMITANT GENE ALTERATIONS IMPACT THE THERAPEUTIC EFFICACY OF EGFR-TKIS IN ADVANCED NSCLC PATIENTS WITH EGFR SENSITIVE MUTATION
    Chang, Cheng-Yu
    Chang, Shih-Chieh
    Lai, Jiun-I
    Lai, Yi-Chun
    RESPIROLOGY, 2019, 24 : 272 - 272
  • [50] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
    He, Qihua
    Liu, Jun
    Cai, Xiuyu
    Li, Caichen
    Liang, Hengrui
    Cheng, Bo
    Xia, Xiaojun
    Guo, Minzhang
    Liang, Peng
    Zhong, Ran
    Li, Feng
    Yu, Ziwen
    Zhao, Yi
    Ou, Limin
    Xiong, Shan
    Li, Jianfu
    Zhang, Jianrong
    He, Jianxing
    Liang, Wenhua
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (11) : 4120 - +
12345